XLRN Acceleron Pharma Inc.

25.25
-1.20  -5%
Previous Close 26.45
Open 26.33
Price To book 4.90
Market Cap 975.08M
Shares 38,617,000
Volume 208,988
Short Ratio 7.03
Av. Daily Volume 403,959

SEC filingsSee all SEC filings

  1. 8-K - Current report 17831588
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17820613
  3. 8-K - Current report 17820551
  4. 8-K - Current report 17805504
  5. 8-K - Current report 17789980

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated by end of 2017.
Luspatercept
Myelofibrosis
Phase 3 trial to be initiated in 2018.
Luspatercept
Myelodysplastic syndromes (MDS) cancer - first-line
Phase 2 trial to be initiated mid-2017.
ACE-083
Charcot-Marie-Tooth disease (CMT)
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment to be completed 2Q 2017 with data due mid-2018.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2Q 2017 with data due mid-2018.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Initial data due late 2017.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 preliminary data due 2Q 2017.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association
  2. Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : May 11, 2017
  3. Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day
  4. Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : May 9, 2017
  5. Edited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT
  6. Why Shares of Biopharma Giant Celgene (CELG) Tumbled Today
  7. How Celgene Toppled On A Small-Cap Biotech's Ragged Quarter
  8. Why Acceleron Pharma Inc. Is Tumbling Today
  9. Acceleron reports 1Q loss
  10. Investor Network: Acceleron Pharma Inc to Host Earnings Call
  11. Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results
  12. Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
  13. Acceleron Announces Management Change
  14. Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
  15. Acceleron to Participate in Two Healthcare Investor Conferences in May
  16. Acceleron Provides Clinical Development Updates on Luspatercept Program
  17. Acceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017
  18. Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes
  19. Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : April 4, 2017